Dror Ortho Design Inc (DROR)

[OMOLIVES]

No..refer:

warrants to purchase up to an aggregate of 964,834,419 shares of Common Stock with a weighted average exercise price of approximately $0.033 per share, of which warrants to purchase 474,999,993 shares of Common Stock were issued to investors in the Private Placement at an exercise price of $0.033 per share.

$31,839,536 capital raise from exercise alone.

outstanding options to purchase up to an aggregate of 179,579,481 shares of Common Stock with a weighted average exercise price of approximately $0.003496 per share; and

$628,528 capital raise(pretty sure that is not cashless given S-1)

AIGH options are a given but the warrants ...depend on circumstances(share price appreciation). I don't want that low of an exercise price...don't want it too high either :)

You just are not going to attract real money and liquidity in the OTC. Most importantly, they wouldn't file and say this:

The primary goal of the Reverse Stock Split is to increase the per share market price of our Common Stock in connection with our intention to apply to have our common stock listed for trading on The Nasdaq Stock Market (“Nasdaq”), as contemplated in the Securities Purchase Agreement. We believe that a range of Reverse Stock Split ratios provides us with the most flexibility to achieve the desired results of the Reverse Stock Split. The Reverse Stock Split is not intended as, and will not have the effect of, a “going private transaction” covered by Rule 13e-3 promulgated under the Exchange Act. The Reverse Stock Split is not intended to modify the rights of existing stockholders in any material respect.

and...

If the Reverse Stock Split Proposal is approved by our stockholders and the Reverse Stock Split is effected, up to every 100,000 shares of our outstanding Common Stock would be combined and reclassified into one share of Common Stock. The actual timing for implementation of the Reverse Stock Split would be determined by the Board based upon its evaluation as to when such action would be most advantageous to the Company and its stockholders Notwithstanding approval of the Reverse Stock Split Proposal by our stockholders, the Board will have the sole authority to elect whether or not and when to amend our amended and restated certificate of incorporation to effect the Reverse Stock Split. If the Reverse Stock Split Proposal is approved by our stockholders, the Board will make a determination as to whether effecting the Reverse Stock Split is in the best interests of the Company and our stockholders in light of, among other things, the Company’s ability to increase the trading price of our Common Stock to meet the minimum stock price standards of Nasdaq without effecting the Reverse Stock Split, the per share price of the Common Stock immediately prior to the Reverse Stock Split and the expected stability of the per share price of the Common Stock following the Reverse Stock Split. If the Board determines that it is in the best interests of the Company and its stockholders to effect the Reverse Stock Split, it will hold a Board meeting to determine the ratio of the Reverse Stock Split. For additional information concerning the factors the Board will consider in deciding whether to effect the Reverse Stock Split, see “— Determination of the Reverse Stock Split Ratio” and “— Board Discretion to Effect the Reverse Stock Split.”

Absolutely nothing will happen here until a form 211 is filed via broker/dealer. As I said..it's still semi dark. The EFFECT(S-1) ..may not happen for at least another Month or two..minimal.

These guys are not the typical bull shit penny guys. TEVA was one of the top 20 largest pharmaceutical companies in the world....and the CEO:

Mr. Haddad has served as our Chief Executive Officer and director since December 2021. Mr. Haddad is a multi-disciplinary finance and technology expert, with extensive senior level operational experience in raising capital, growing complex business models, and guiding startups and later stage companies to successful exits. Prior to his employment at Dror, Mr. Haddad served as Chief Executive Officer of HFT Investments from 2007 through 2021. He also served as a Senior Adviser at Exceed Talent Capital between 2019 and 2023. Over the course of his 30-year career, Mr. Haddad has structured and managed a number of technology and media transactions valued at an aggregate of over $85 billion, including $250 million in transactions within the Israeli high-tech space in AI, medical technology, and cybersecurity. Mr. Haddad received a bachelor’s degree in economics and philosophy from Columbia University, where he was the recipient of the National Science Foundation Award in Theoretical Physics and started his career in the M&A subgroup of Morgan Stanley’s media and technology group for several years. We believe that Mr. Haddad’s extensive business experience qualifies him to serve as a member of our Board.

So what do you think? There is a good chance that it whips up beforehand...I just tend to not be so over optimistic at that. Mainly because the OTC sucks currently. If this were some years back...whole different story. Actually...if it were some years back, you would have already closed out with a banger. That's how shitty it is now ...